Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
Date
2021-03
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A
Abstract
Anticancer drugs are an essential part of cancer treatment. Cancer cells can, however, develop resistance to these drugs by e.g., P-glycoprotein 1 (P-gp) overexpression or accumulation of mutations in the genes part of growth signaling pathways, apoptotic pathways, or repair system. Intrinsically, metastatic cancers, advanced-stage cancers, or stem cell-like cancers are usually drug-resistant and difficult to treat using current anticancer drugs. The overexpression of P-gp, also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1), is one of the well-known mechanisms of resistance to anticancer drugs. Stem cell-like cancers often overexpress P-gp on their membranes, which results in inefficient treatment using the currently available anticancer drugs (1). It is, therefore, important to investigate novel therapeutic options to treat the P-gp overexpressing drug-resistant cancer cells. Identifying the mechanisms for targeting these cancers can overcome the inefficiencies of current anticancer drugs and lead to better outcomes for patients with P-gp overexpressing cancers.
Description
CITATION: Yoon S, Wang X, Vongpunsawad S, Tromp G and Kuivaniemi H (2021) Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer. Front. Oncol. 11:632657.
doi.10.3389/fonc.2021.632657
The original publication is available at: frontiersin.org
The original publication is available at: frontiersin.org
Keywords
Antineoplastic agents, Drug resistance in cancer cells, P-gp overexpresssion, MDR, Anticancer drug, Molecular targeting, Cancer -- Treatment, P-glycoprotein
Citation
Yoon S, Wang X, Vongpunsawad S, Tromp G and Kuivaniemi H (2021) Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer. Front. Oncol. 11:632657.
doi.10.3389/fonc.2021.632657